GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silverback Therapeutics Inc (NAS:SBTX) » Definitions » Cyclically Adjusted PB Ratio

Silverback Therapeutics (Silverback Therapeutics) Cyclically Adjusted PB Ratio : (As of May. 08, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Silverback Therapeutics Cyclically Adjusted PB Ratio?

Silverback Therapeutics does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Silverback Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Silverback Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silverback Therapeutics Cyclically Adjusted PB Ratio Chart

Silverback Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PB Ratio
- - - -

Silverback Therapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Silverback Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Silverback Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silverback Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silverback Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Silverback Therapeutics's Cyclically Adjusted PB Ratio falls into.



Silverback Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Silverback Therapeutics does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.


Silverback Therapeutics  (NAS:SBTX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Silverback Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Silverback Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Silverback Therapeutics (Silverback Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
500 Fairview Avenue N, Suite 600, Seattle, WA, USA, 98109
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
Executives
Brian Dorsey officer: Chief Operating Officer C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Alexander A Fitzpatrick officer: Chief Legal Officer 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Brent L Saunders director 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Pratik Shah Living Trust Dated June 15, 2011 10 percent owner C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Michael Kelly director C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Rajeev Dadoo director C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Sarina Tanimoto 10 percent owner, officer: Chief Medical Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Eric Karas officer: Chief Commercial Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Justin Chakma officer: Chief Business Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Richard E Lowenthal director, 10 percent owner, officer: President and CEO 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Pratik Shah director, 10 percent owner 3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Ra Capital Nexus Fund Ii, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kathleen D. Scott officer: Chief Financial Officer C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Deerfield Mgmt Iv, L.p. director, 10 percent owner, other: * Director by deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p. director, 10 percent owner, other: * Director by deputization 780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017

Silverback Therapeutics (Silverback Therapeutics) Headlines

From GuruFocus

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

By Business Wire Business Wire 07-21-2022